Oppenheimer upgraded Compass Pathways (CMPS) to Outperform from Perform with a $15 price target
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPS:
- Buy Rating for COMPASS Pathways: Accelerated Clinical Development and Strategic Position in Mental Health Sector
- Psychedelic: Compass Pathways, GH Research report Q3 earnings
- Compass Pathways Accelerates Launch Plans Amid Positive FDA Talks
- Compass Pathways Earnings Call Highlights Progress and Plans
- Accelerated Phase 3 Timeline and Strong Financials Boost COMPASS Pathways’ Prospects